Updates are available Correction dated 2020-06-15

Article History

Received: 5 July 2018

Accepted: 21 December 2018

First Online: 11 February 2019

Change Date: 15 June 2020

Change Type: Correction

Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Competing interests

: B.P.K. is a scientific advisor to Avectas. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.K.J. has financial interests in Beam Therapeutics, Blink Therapeutics, Editas Medicine, Endcadia, Monitor Biotechnologies (formerly known as Beacon Genomics), Pairwise Plants, Poseida Therapeutics and Transposagen Biopharmaceuticals. M.J.A. has financial interests in Monitor Biotechnologies. J.K.J. holds equity in EpiLogic Therapeutics. J.K.J.’s and M.J.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. B.P.K., A.A.S., and J.K.J. are inventors on patent applications covering the Cas12a variants described in this work. Y.E.T., B.P.K. and J.K.J. are inventors on a patent application describing Cas12-based transcriptional activators. M.V.M. reports personal fees from Adaptimmune, personal fees from Adaptive Biotechnologies, grants and personal fees from Agentus, personal fees from Bluebird Bio, personal fees from Cellectis, grants and personal fees from CRISPR Therapeutics, personal fees from Incysus, grants and personal fees from Kite Pharma, personal fees from Juno, personal fees from MPM, personal fees from Novartis, personal fees from Takeda, grants and personal fees from TCR2 (SAB), personal fees from Third Rock Ventures, personal fees from Windmil (SAB) and personal fees from Century, outside the submitted work. M.V.M. has a patent related to CAR T cells for multiple myeloma, lymphoma and glioblastoma (none of which are the subject of this manuscript) pending.